CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Lyell Immunopharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Lyell Immunopharma Inc
201 Haskins Way, Suite 301
Phone: (650) 695-0677p:650 695-0677 SOUTH SAN FRANCISCO, CA  94080  United States Ticker: LYELLYEL
Business Summary
Lyell Immunopharma, Inc. is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. The Company has only one product candidate, LYL314, in Phase I/II clinical development. LYL314 is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. LYL314 is designed with a true 'OR' logic gate to target B cells that express either CD19 or CD20 with full potency and is manufactured with a process that enriches for CD62L-positive cells to generate more naive and central memory CAR T cells with enhanced stemlike features and antitumor activity.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202512/31/2024YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Richard D.Klausner 73 12/2/2021 10/1/2021
President, Chief Executive Officer, Director LynnSeely 66 12/15/2022 5/1/2021
Chief Financial Officer CharlesNewton 54 2/1/2021 2/1/2021
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
ImmPACT Bio USA, Inc. 8501 Fallbrook Avenue, Suite 200 West Hills CA United States

Business Names
Business Name
ImmPACT Bio USA, Inc.
LYEL

General Information
Number of Employees: 300 (As of 12/31/2024)
Outstanding Shares: 14,808,078 (As of 6/2/2025)
Shareholders: 73
Stock Exchange: NASD
Federal Tax Id: 833006753
Fax Number: (302) 531-3150


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, June 6, 2025